Optimal response to tislelizumab plus chemotherapy in metastatic triple-negative breast cancer: a case report and literature review

Yuxin Ma; Xinhong Shi; Kun Zhao; Shuyi Hu; Yue Shi; Yingying Jiang; Yiling Liu; Lin Lu; Yuting Chang; Fei Zhou; Yingying Dai; Zipeng Wu; Shiyi Li; Zhiying Qian; Xia Xu; Chenchen Li; Bo Shen; Guoren Zhou; Cheng Chen; Xiaohua Wang; Jifeng Feng

doi:10.3389/fonc.2024.1328844

Optimal response to tislelizumab plus chemotherapy in metastatic triple-negative breast cancer: a case report and literature review

Front Oncol. 2024 Mar 28:14:1328844. doi: 10.3389/fonc.2024.1328844. eCollection 2024.

Authors

Yuxin Ma¹, Xinhong Shi¹, Kun Zhao², Shuyi Hu¹, Yue Shi¹, Yingying Jiang³, Yiling Liu¹, Lin Lu¹, Yuting Chang¹, Fei Zhou¹, Yingying Dai¹, Zipeng Wu¹, Shiyi Li¹, Zhiying Qian¹, Xia Xu¹, Chenchen Li¹, Bo Shen^{1

2}, Guoren Zhou¹, Cheng Chen¹, Xiaohua Wang^{1

2}, Jifeng Feng^{1

2}

Affiliations

¹ Department of Medical Oncology, The Affiliated Cancer Hospital of Nanjing Medical University & Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research, Nanjing, Jiangsu, China.
² Huaian Hospital of Huaian City, Huaian Cancer Hospital, Huaian, Jiangsu, China.
³ Department of Oncology, Province Geriatric Hospital, Nanjing, Jiangsu, China.

Abstract

Metastatic triple-negative breast cancer (mTNBC) has the worst prognosis among breast cancer subtypes. Immune checkpoint inhibitors (ICIs) plus chemotherapy have promising survival benefits. Herein, we report a 51-year-old woman whose metastatic lesions were diagnosed as triple-negative subtype and who received tislelizumab plus eribulin treatment and achieved excellent efficacy. To our knowledge, this study is the first attempt to present tislelizumab in combination with eribulin for mTNBC treatment. New treatments resulting in prolonged survival and durable clinical responses would benefit mTNBC patients. Then, we summarize the possible influencing factors of the interaction between tislelizumab and eribulin.

Keywords: case report; eribulin mesylate; immune checkpoint inhibitors (ICIS); metastatic triple negative breast cancer (mTNBC); tislelizumab.

Publication types

Case Reports

Grants and funding

The author(s) declare financial support was received for the research, authorship, and/or publication of this article. Science foundation item: (Y2018088, Z2021008).